ArticleFrontiers in psychiatry2026
Real-world adherence, healthcare resource utilization, and costs following a transition to aripiprazole once every 2 months among patients diagnosed with bipolar I disorder in the United States.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transitioning from oral to long-acting injectable (LAI) antipsychotics may improve adherence and reduce healthcare resource utilization (HCRU) in patients living with bipolar I disorder (BP-I), with potentially greater improvements with LAIs with dosing intervals longer than 1 month. Aripiprazole monohydrate is available as LAI formulations administered once-monthly [aripiprazole once-monthly (AOM)] or once every 2 months (aripiprazole 2-month ready-to-use [Ari 2MRTU]). This pre-post analysis described adherence, HCRU, and costs over 6 months in adults diagnosed with BP-I who transitioned from oral antipsychotics or AOM to Ari 2MRTU. Methods: This retrospective, noninterventional study used Kythera Labs United States closed claims to identify adults diagnosed with BP-I, commercially or Medicaid-insured, and who transitioned from oral antipsychotics or AOM to Ari 2MRTU from April 2023-September 2024 (index date = Ari 2MRTU transition). Continuous enrollment for 12 months pre- and 6 months post-index was required. Study outcomes were compared 6 months prior to and following the index date. Results: Among those who transitioned from oral antipsychotics to Ari 2MRTU (n = 371),mean proportion of days covered (PDC) increased from 0.60 to 0.76 (26.2% relative increase), mean medication possession ratio (MPR) increased from 0.67 to 0.85 (26.8% relative increase), and proportion of patients with MPR ≥ 0.8 increased from 41.2% to 72.0% (74.5% relative increase) (all Discussion: Transitioning to Ari 2MRTU was associated with improved treatment adherence and reduced selected HCRU measures and total medical costs, supporting its value as a treatment option for BP-I.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.